US Patent
US8193182 — Substituted isoquinolin-1(2H)-ones, and methods of use thereof
Composition of Matter · Assigned to Intellikine LLC · Expires 2032-09-24 · 6y remaining
Vulnerability score
4/100
Ironclad — strong claim type, well-established, deep family
What this patent protects
This patent protects chemical entities that modulate PI3 kinase activity and their methods of use for treating diseases and conditions associated with PI3 kinase activity.
USPTO Abstract
Chemical entities of Formula I: that modulate PI3 kinase activity, pharmaceutical compositions containing the chemical entities, and methods of using these chemical entities for treating diseases and conditions associated with P13 kinase activity are described herein.
Drugs covered by this patent
- Copiktra (DUVELISIB) · Secura
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.